Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Rocket Pharmaceuticals Stock Quote

Rocket Pharmaceuticals (NASDAQ: RCKT)

$22.16
(-6.2%)
-$1.47
Price as of April 25, 2024, 2:25 p.m. ET

Rocket Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
RCKT +32.98% +25.62% +4.67% +89%
S&P +24.56% +72.51% +11.52% +85%

Rocket Pharmaceuticals Company Info

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.